<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26765">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02758301</url>
  </required_header>
  <id_info>
    <org_study_id>LINQ HF</org_study_id>
    <nct_id>NCT02758301</nct_id>
  </id_info>
  <brief_title>Reveal LINQ™ Heart Failure</brief_title>
  <acronym>LINQ HF</acronym>
  <official_title>Reveal LINQ™ Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiac Rhythm and Heart Failure</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiac Rhythm and Heart Failure</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the LINQ™ HF study is to characterize Reveal LINQ™ derived data from patients
      with heart failure by assessing the relationship between changes in LINQ™ derived data and
      other physiologic parameters with subsequent acute decompensated heart failure (ADHF)
      events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a prospective, non-randomized, multi-center, observational, pre-market clinical
      study. The study is expected to be conducted at up to 30 centers in the United States. Up to
      300 subjects will be enrolled to achieve approximately 40 heart failure events (no more than
      two per subject will contribute to the cumulative total). Study subjects will be followed
      for up to 3 years post-insertion or until official study closure defined as when Medtronic
      and/or regulatory requirements have been satisfied per the Clinical Investigation Plan
      and/or by a decision by Medtronic or regulatory authority, whichever occurs first. The
      expected study duration is approximately 4 years representing 1.5 years of enrollments and
      2.5 years of follow-up.

      The LINQ™ HF study is a Non-Significant Risk Investigational Device Exemption (IDE) study.
      The study is utilizing the Reveal LINQ™ device with an investigational LINQ™ HF RAMware
      download.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Acute Decompensated Heart Failure events</measure>
    <time_frame>30 days post-implant to 3 years post-implant</time_frame>
    <description>A heart failure (HF) event is defined as any cardiovascular-related Health Care Utilizations (HCUs) for any one of the following events.
Admission with primary diagnosis of HF
Intravenous HF therapy (e.g. IV diuretics/vasodilators) or ultrafiltration at any one of the following settings:
Admission with secondary/tertiary diagnosis of HF
Emergency Department
Ambulance
Observation Unit
Urgent Care
HF/Cardiology Clinic</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Second Acute Decompensated Heart Failure events</measure>
    <time_frame>90 days following first Acute Decompensated Heart Failure event to 3 years post-implant</time_frame>
    <description>A heart failure (HF) event is defined as any cardiovascular-related Health Care Utilizations (HCUs) for any one of the following events.
Admission with primary diagnosis of HF
Intravenous HF therapy (e.g. IV diuretics/vasodilators) or ultrafiltration at any one of the following settings:
Admission with secondary/tertiary diagnosis of HF
Emergency Department
Ambulance
Observation Unit
Urgent Care
HF/Cardiology Clinic</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Diagnostic</arm_group_label>
    <description>The Reveal LINQ™ Insertable Cardiac Monitor (ICM) device will be inserted in all subjects for continuous monitoring. After the Reveal LINQ™ device is inserted, the LINQ™ HF investigational RAMware will be downloaded to the LINQ™ ICM.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Reveal LINQ™ Insertable Cardiac Monitor (ICM)</intervention_name>
    <description>Insertable Cardiac Monitor with LINQ™ HF Investigational RAMware download</description>
    <arm_group_label>Diagnostic</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The subject population for the LINQ™ HF study is patients with heart failure with a NYHA
        Class III who meet all of the inclusion and none of the exclusion criteria.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is 18 years of age or older

          -  Patient (or patient's legally authorized representative) is willing and able to
             provide written informed consent

          -  Patient is willing and able to comply with the protocol, including follow-up visits
             and Carelink transmissions.

          -  Patient is NYHA Class III, per most recent assessment or at any time within 30 days
             prior to enrollment

          -  Patient had a HF event (HF event defined as meeting any one of the following three
             criteria):

               1. Admission with primary diagnosis of HF within the last 6 months, OR

               2. Intravenous HF therapy (e.g. IV diuretics/vasodilators) or ultrafiltration at
                  any one of the following settings within the last 6 months:

                    -  Admission with secondary/tertiary diagnosis of HF

                    -  Emergency Department

                    -  Ambulance

                    -  Observation Unit

                    -  Urgent Care

                    -  HF/Cardiology Clinic

                    -  Patient's Home, OR

               3. Patient had the following BNP/NTpro-BNP within the last 3 months: If EF ≥ 50%,
                  then BNP&gt; 200 pg/ml or NTpro-BNP &gt; 400 pg/ml OR If EF &lt;50%, then BNP&gt; 400 pg/ml
                  or NTpro-BNP &gt; 800 pg/ml

        Exclusion Criteria:

          -  Patient is pregnant (all females of child-bearing potential must have a negative
             pregnancy test within 1 week of enrollment)

          -  Patient is enrolled in another study that could confound the results of this study,
             without documented pre-approval from a Medtronic study manager

          -  Patient has severe valvular heart disease as defined by hemodynamically significant
             valve stenosis and/or prosthetic heart valve

          -  Patient has existing IPG, ICD, CRT-D or CRT-P device

          -  Patient has severe renal impairment (eGFR &lt;25mL/min)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kara L Southall, Prin. Clinical Research Spec.</last_name>
    <phone>612-963-2640</phone>
    <email>kara.l.southall@medtronic.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aimee A Laechelt, Sr. Clinical Research Spec.</last_name>
    <phone>763-526-2730</phone>
    <email>aimee.a.laechelt@medtronic.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bay Area Cardiology Associates PA</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen W Mester, MD</last_name>
      <email>bac.research@bayareacardiology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prairie Education &amp; Research Cooperative</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Stampehl, MD</last_name>
      <email>mstampehl@prairieheart.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Louisiana State University</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Smart, MD</last_name>
      <email>fsmart@lsuhsc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sparrow Clinical Research Institute</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>T. Michael Brown, MD</last_name>
      <email>mbrown@tciheart.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cardiology Associates of North Mississippi</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barry Bertolet, MD</last_name>
      <email>bbertolet@nmhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory Ewald, MD</last_name>
      <email>gewald@dom.wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lourdes Cardiology Services</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Mohapatra, MD</last_name>
      <email>bmohapatra@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanjeev Gulati, MD</last_name>
      <email>sanjeev.gulati@carolinashealthcare.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Lindner Research Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eugene Chung, MD</last_name>
      <email>Eugene.Chung@thechristhospital.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rami Kahwash, MD</last_name>
      <email>rami.kahwash@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lancaster General Hospital</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roy Small, MD</last_name>
      <email>rssmall@lghealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee Goldberg, MD</last_name>
      <email>lee.goldberg@uphs.upenn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Austin Heart PA</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kunjan Bhatt, MD</last_name>
      <email>kunjan.bhatt@hcahealthcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Kennedy, MD</last_name>
      <email>jlk4b@virginia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centra Medical Group Stroobants Cardiovascular Center</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Rennyson, MD</last_name>
      <email>stephen.rennyson@centrahealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sentara Norfolk General Hospital</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Herre, MD</last_name>
      <email>jmherre1@aol.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 17, 2016</lastchanged_date>
  <firstreceived_date>April 27, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
